In a report released yesterday, Derek Archila from Wells Fargo assigned a Buy rating to Cabaletta Bio (CABA – Research Report), with a price target of $35.00. The company’s shares closed yesterday at $17.54.
According to TipRanks, Archila is a 4-star analyst with an average return of 8.4% and a 44.39% success rate. Archila covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Exelixis, and Argenx Se.
Cabaletta Bio has an analyst consensus of Strong Buy, with a price target consensus of $34.33.
The company has a one-year high of $26.35 and a one-year low of $6.94. Currently, Cabaletta Bio has an average volume of 883.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cabaletta Bio (CABA) Company Description:
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.
Read More on CABA:
- Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Cabaletta Bio Receives Orphan Drug Status for CABA-201
- Cabaletta Bio granted Orphan Drug designation to CABA-201
- Cabaletta Bio treatment of systemic sclerosis granted orphan designation
- Cabaletta Bio, Inc. (CABA) Q4 Earnings Cheat Sheet
